Search for other papers by Giacomo Sturniolo in
Google Scholar
PubMed
Search for other papers by Carles Zafon in
Google Scholar
PubMed
Search for other papers by Mariacarla Moleti in
Google Scholar
PubMed
Search for other papers by Josep Castellví in
Google Scholar
PubMed
Search for other papers by Francesco Vermiglio in
Google Scholar
PubMed
Search for other papers by Jordi Mesa in
Google Scholar
PubMed
several studies have investigated the expression of estrogen receptor (ER) subtypes in thyroid cancers. However, results are not consistent yet, likely because of the existence of confounding factors in the populations selected [ 15 , 16 ]. The purpose
Search for other papers by Julia Ramalho Amalio da Silva Breder in
Google Scholar
PubMed
Search for other papers by Paulo Alonso Garcia Alves in
Google Scholar
PubMed
Search for other papers by Mario Lucio Araújo in
Google Scholar
PubMed
Search for other papers by Barbara Pires in
Google Scholar
PubMed
Search for other papers by Priscila Valverde in
Google Scholar
PubMed
Search for other papers by Daniel Alves Bulzico in
Google Scholar
PubMed
Search for other papers by Fernanda Andrade Accioly in
Google Scholar
PubMed
Search for other papers by Rossana Corbo in
Google Scholar
PubMed
Search for other papers by Mario Vaisman in
Google Scholar
PubMed
Endocrinology Department, Instituto Nacional do Cancer do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil
Search for other papers by Fernanda Vaisman in
Google Scholar
PubMed
demonstrated the presence of estrogen receptor (ER) in thyroid tumor cells in adults ( 11 , 12 , 13 , 14 , 15 ). In many studies, ERα positivity has been associated with larger primary tumor size, suggesting that estrogen may act as a growth factor in
Search for other papers by Sara Donato in
Google Scholar
PubMed
NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal
Search for other papers by Helder Simões in
Google Scholar
PubMed
NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal
Unidade de Investigação em Patobiologia Molecular, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
pregnancy may represent a stimulus for DTC growth in patients with structural or biochemical evidence of disease [ 8 ], possibly due to the high levels of estrogen that occur during that physiological state, which can bind to receptors present in cancer
Search for other papers by Sepehr Torabinejad in
Google Scholar
PubMed
Search for other papers by Caterina Miro in
Google Scholar
PubMed
Search for other papers by Biagio Barone in
Google Scholar
PubMed
Search for other papers by Ciro Imbimbo in
Google Scholar
PubMed
Search for other papers by Felice Crocetto in
Google Scholar
PubMed
CEINGE – Biotecnologie Avanzate Scarl, Naples, Italy
Search for other papers by Monica Dentice in
Google Scholar
PubMed
RGGTCA (R is a purine). Based on their mode of action, they can be subdivided into four different sub-categories: (i) Type I receptors, comprising the AR, the estrogen receptor (ER), and the progesterone receptor (PR), are anchored in the cytoplasm by
Search for other papers by Bharath Bachimanchi in
Google Scholar
PubMed
Search for other papers by Suresh Vaikkakara in
Google Scholar
PubMed
Search for other papers by Alok Sachan in
Google Scholar
PubMed
Search for other papers by Ganji Praveen Kumar in
Google Scholar
PubMed
Search for other papers by Ashok Venkatanarasu in
Google Scholar
PubMed
Search for other papers by Palaparti Sai Krishna Chaitanya in
Google Scholar
PubMed
Search for other papers by Bekkem Sreedivya in
Google Scholar
PubMed
Search for other papers by Ravi Poojari in
Google Scholar
PubMed
estrogen (< 73.42 pmol/L) levels. These 5 had higher TSH (> 100 vs. 78.8 mIU/L in women with normal estrogen; p = 0.036). PRL was higher in the hypoestrogenic women, while both the gonadotropins (LH and FSH) were lower (Table 2 ). Table 2
Search for other papers by Joachim M. Weitzel in
Google Scholar
PubMed
. Biochem J 2009;419:167-176. 10.1042/BJ20081556 19067653 23 Wilson BJ, Tremblay AM, Deblois G, Sylvain-Drolet G, Giguere V: An acetylation switch modulates the transcriptional activity of estrogen-related receptor alpha. Mol Endocrinol 2010
Search for other papers by Denise Zwanziger in
Google Scholar
PubMed
Search for other papers by Helena Rakov in
Google Scholar
PubMed
Search for other papers by Kathrin Engels in
Google Scholar
PubMed
Search for other papers by Lars C. Moeller in
Google Scholar
PubMed
Search for other papers by Dagmar Führer in
Google Scholar
PubMed
-1 liver expression with different thyroid states, a possible interaction between estradiol and TH may be involved. These seems more likely when it is considered that both receptors - THRs and estrogen - belong to the superfamily of nuclear receptors
Search for other papers by R. Burns in
Google Scholar
PubMed
National Maternity Hospital, Dublin, Ireland
Search for other papers by C. O'Herlihy in
Google Scholar
PubMed
Search for other papers by P.P.A. Smyth in
Google Scholar
PubMed
of estrogen, receptors in the developing human placenta. Horm Metab Res 1997;29:604-610. 10.1055/s-2007-979109 9497895 33 Shanker YG, Rao AJ: Progesterone receptor expression in the human placenta. Mol Hum Reprod 1999;5:481-486. 10.1093/molehr
Search for other papers by Thea Riis in
Google Scholar
PubMed
Search for other papers by Steen Joop Bonnema in
Google Scholar
PubMed
Search for other papers by Thomas Heiberg Brix in
Google Scholar
PubMed
Search for other papers by Lars Folkestad in
Google Scholar
PubMed
hormones induced human lung cancer cell proliferation via crosstalk between integrin αvβ3 and estrogen receptor alpha. In a study in mice, thyroxine enhanced the weight of Lewis’ carcinoma and angiogenesis, but this required the activation of integrin αvβ3
Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Search for other papers by Georg Brabant in
Google Scholar
PubMed
Search for other papers by Mehul Dattani in
Google Scholar
PubMed
Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Search for other papers by Marco Bonomi in
Google Scholar
PubMed
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Search for other papers by Eric Fliers in
Google Scholar
PubMed
University Hospital Heidelberg, Heidelberg, Germany
Search for other papers by Annette Gruters in
Google Scholar
PubMed
Search for other papers by Dominique Maiter in
Google Scholar
PubMed
Search for other papers by Nadia Schoenmakers in
Google Scholar
PubMed
Search for other papers by A.S. Paul van Trotsenburg in
Google Scholar
PubMed
with recombinant human growth hormone (rhGH) or estrogen (see [ 1 ]) (Recommendation 8) as well as in those receiving particular drugs (Recommendation 9), in particular rexinoids (like bexarotene, an agonist of retinoid X receptor that is approved for